e-learning
resources
ERJ
2008
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Possible role of imatinib in clinical pulmonary veno-occlusive disease
Overbeek, M. J., van Nieuw Amerongen, G. P., Boonstra, A., Smit, E. F., Vonk-Noordegraaf, A.
Source:
Eur Respir J 2008; 32: 232-235
Journal Issue:
July
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Overbeek, M. J., van Nieuw Amerongen, G. P., Boonstra, A., Smit, E. F., Vonk-Noordegraaf, A.. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 2008; 32: 232-235
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Dual mechanism of platelet-derived growth factor (PDGF)-receptor: Contribution of vascular response to the pathogenesis of pulmonary hypertension (PH)
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017
Year: 2018
PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Pulmonary vascular involvement in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: 28S-32S
Year: 2003
Novel treatment for pulmonary vascular disease: lessons from pathophysiology
Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases
Year: 2006
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Single arterial occlusion to locate resistance in patients with pulmonary hypertension
Source: Eur Respir J 2003; 21: 31-36
Year: 2003
Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature
Source: Eur Respir J 2014; 44: 1275-1288
Year: 2014
Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target
Source: Eur Respir J 2011; 38: 1453-1460
Year: 2011
Chronic thromboembolic pulmonary hypertension: role of medical therapy
Source: Eur Respir J 2013; 41: 985-990
Year: 2013
Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
Source: Eur Respir J 2009; 34: 1348-1356
Year: 2009
Pulmonary hypertension: the science behind the disease spectrum
Source: Eur Respir Rev 2012; 21: 19-26
Year: 2012
Pulmonary hypertension in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 892-905
Year: 2003
Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Pulmonary hypertension and pulmonary vascular disease: course report
Source: Breathe, 14 (1) e4; 10.1183/20734735.019917
Year: 2018
Transforming growth factor-β type II receptor in pulmonary arteries of patients with very severe COPD
Source: Eur Respir J 2006; 28: 556-562
Year: 2006
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006
Pulmonary hypertension in sickle cell disease
Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease
Year: 2007
Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease
Source: Annual Congress 2012 - Sarcoidosis
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept